As regulatory frameworks tighten and global headwinds disrupt some elements of traditional collaboration models, biotech dealmaking is facing new challenges. This discussion highlights the tools, terms, and strategic approaches that companies are using to build resilient, value creating transactions in an unpredictable environment.
Tuesday, May 5, 16:00 - 16:45, room Delhi
| Name | Position | Institution |
|---|---|---|
| Schieber Julia | Partner (Zurich) | Baker McKenzie |
| Name | Position | Institution |
|---|---|---|
| Livne Oren | Partner (New-York) | Baker McKenzie |
Baker McKenzie is one of the largest law firms in Switzerland, with offices in Geneva and Zurich. With more than 120 lawyers, we are a leading force in the Swiss market, advising domestic and international clients. With long‑standing experience supporting HLS companies in their global expansion, we understand industry challenges and how to address them. Backed by 800+ lawyers worldwide and a presence in more than 70 offices across 45 countries, we offer comprehensive transactional, regulatory, tax and IP support to the world’s largest pharma, biotech, medical device, medtech, digital health and healthcare services companies.
